Scarica l'app Stockscreener
74.93
2.08%
1.53
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HALO Giù?
Forum
Previsione
Precedente Chiudi:
$73.40
Aprire:
$73.67
Volume 24 ore:
1.89M
Relative Volume:
0.87
Capitalizzazione di mercato:
$8.76M
Reddito:
$947.36M
Utile/perdita netta:
$392.47M
Rapporto P/E:
24.81
EPS:
3.02
Flusso di cassa netto:
$392.71M
1 W Prestazione:
+2.43%
1M Prestazione:
+23.22%
6M Prestazione:
+25.87%
1 anno Prestazione:
+22.74%
Intervallo 1D:
$72.39
$74.96
Intervallo di 1 settimana:
$71.50
$75.46
Portata 52W:
$42.01
$75.46
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Nome
Halozyme Therapeutics Inc
Settore
Industria
Telefono
(858) 794-8889
Indirizzo
12390 EL CAMINO REAL, SAN DIEGO, CA
Confronta HALO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
74.93 | 8.59B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-06 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-10 | Ripresa | Goldman | Neutral |
| 2025-05-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Downgrade | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-06-07 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | Iniziato | TD Cowen | Outperform |
| 2023-07-24 | Downgrade | Goldman | Buy → Neutral |
| 2023-07-24 | Iniziato | H.C. Wainwright | Buy |
| 2023-05-10 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Ripresa | Berenberg | Buy |
| 2023-03-16 | Downgrade | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | Ripresa | Morgan Stanley | Overweight |
| 2022-11-28 | Iniziato | Wells Fargo | Overweight |
| 2022-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2021-06-14 | Iniziato | Evercore ISI | Outperform |
| 2021-05-17 | Iniziato | SVB Leerink | Outperform |
| 2021-05-11 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | Reiterato | The Benchmark Company | Buy |
| 2020-12-17 | Iniziato | Berenberg | Buy |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-07-01 | Iniziato | The Benchmark Company | Buy |
| 2020-02-05 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | Iniziato | Goldman | Buy |
| 2019-11-05 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2018-10-19 | Ripresa | Piper Jaffray | Neutral |
| 2018-05-11 | Downgrade | Barclays | Equal Weight → Underweight |
| 2018-01-24 | Iniziato | Goldman | Neutral |
| 2017-10-16 | Reiterato | Piper Jaffray | Overweight |
| 2017-01-06 | Downgrade | Citigroup | Buy → Neutral |
| 2016-11-03 | Iniziato | Deutsche Bank | Buy |
| 2015-12-04 | Iniziato | Wells Fargo | Outperform |
| 2015-11-18 | Iniziato | Citigroup | Buy |
| 2015-09-22 | Iniziato | Barclays | Overweight |
| 2015-06-22 | Reiterato | JP Morgan | Overweight |
| 2015-03-03 | Reiterato | UBS | Buy |
| 2015-02-18 | Reiterato | MLV & Co | Buy |
| 2015-01-08 | Reiterato | MLV & Co | Buy |
Mostra tutto
Halozyme Therapeutics Inc Borsa (HALO) Ultime notizie
Halozyme Therapeutics Inc. stock prediction for this weekWeekly Trade Summary & Real-Time Buy Signal Notifications - Newser
RYBREVANT®▼ (amivantamab) plus LAZCLUZE®▼ (lazertinib) reduces acquired resistance versus osimertinib in first-line EGFR-mutated advanced non-small cell lung cancer - GlobeNewswire Inc.
What drives Halozyme Therapeutics Inc.’s stock priceJuly 2025 Price Swings & Stepwise Trade Signal Guides - خودرو بانک
What to do if you’re stuck in Halozyme Therapeutics Inc.Market Rally & Smart Investment Allocation Tips - Newser
Zacks.com featured highlights include Halozyme Therapeutics, Phibro, Leidos and PDD Holdings - Yahoo Finance
Bet on These 3 Stocks With Upgraded Broker Ratings for Robust Returns - Yahoo Finance
Forecasting Halozyme Therapeutics Inc. price range with options dataDividend Hike & Weekly High Return Stock Forecasts - Newser
Is Halozyme Therapeutics Inc. stock entering bullish territory2025 Market WrapUp & Safe Capital Growth Tips - Newser
Halozyme Therapeutics Inc. stock chart pattern explainedLong Setup & Technical Entry and Exit Alerts - Newser
Applying Wyckoff theory to Halozyme Therapeutics Inc. stockMarket Volume Report & Accurate Intraday Trade Tips - Newser
Halozyme Therapeutics Inc. recovery potential after sell off2025 Key Lessons & Weekly Top Stock Performers List - Newser
Halozyme at Wells Fargo Conference: Strategic Growth and Challenges By Investing.com - Investing.com Canada
Halozyme Therapeutics (HALO): Revolutionizing Drug Delivery and Scaling Commercial Success - AInvest
Halozyme Therapeutics Presents at Wells Fargo 20th Annual Healthcare Conference 2025: Q&A Session with Helen Torley - AInvest
Halozyme up after guidance raise, Morgan Stanley upgrade - MSN
Transcript : Halozyme Therapeutics, Inc. Presents at Wells Fargo 20th Annual Healthcare Conference 2025, Sep-04-2025 01 - MarketScreener
4 PEG-Rated GARP Stocks That Offer Both Value and Growth - Zacks Investment Research
Leading vs lagging indicators on Halozyme Therapeutics Inc. performance2025 Earnings Surprises & AI Powered Buy and Sell Recommendations - Newser
Will Halozyme Therapeutics Inc. outperform the marketQuarterly Trade Summary & Free Safe Entry Trade Signal Reports - Newser
What to expect from Halozyme Therapeutics Inc. in the next 30 daysPortfolio Gains Summary & Free Community Supported Trade Ideas - Newser
Halozyme Therapeutics stock reaches all-time high at 74.79 USD By Investing.com - Investing.com Canada
Trend analysis for Halozyme Therapeutics Inc. this weekJuly 2025 Technicals & Safe Capital Growth Plans - Newser
Visual trend scoring systems applied to Halozyme Therapeutics Inc.Weekly Stock Summary & Long-Term Growth Stock Strategies - Newser
Are You Looking for a Top Momentum Pick? Why Halozyme Therapeutics (HALO) is a Great Choice - sharewise.com
Connaughton sells Halozyme Therapeutics (HALO) stock worth $294,736 By Investing.com - Investing.com Australia
Halozyme Therapeutics (HALO)A Momentum Leader with Strong Performance - AInvest
Halozyme Therapeutics stock reaches all-time high at 74.79 USD - Investing.com
Halozyme Therapeutics and atai Life Sciences N.V. Lead Medical Stocks with 53.4% and 245.1% Year-to-Date Returns Respectively. - AInvest
Best Momentum Stock to Buy for September 3rd - TradingView
Are Medical Stocks Lagging Halozyme Therapeutics (HALO) This Year? - Yahoo Finance
How to Find Strong Buy Medical Stocks Using the Zacks Rank - Yahoo Finance
Halozyme Therapeutics, Inc. (HALO) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
Investors Still Aren't Entirely Convinced By Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) Earnings Despite 26% Price Jump - 富途牛牛
New Strong Buy Stocks for September 3rd - The Globe and Mail
Analyzing net buyer seller activity in Halozyme Therapeutics Inc.2025 Analyst Calls & Low Risk High Reward Ideas - Newser
Published on: 2025-09-03 04:54:32 - Newser
Halozyme Therapeutics Inc. stock volume spike explainedTrade Analysis Report & Fast Gain Stock Trading Tips - Newser
Connaughton sells Halozyme Therapeutics (HALO) stock worth $294,736 - Investing.com
What is Halozyme Therapeutics Inc. s P E ratio telling usJuly 2025 PreEarnings & Short-Term High Return Strategies - خودرو بانک
RSI + MACD Show Convergence for Halozyme Therapeutics Inc.Bull Run & Free Expert Verified Stock Movement Alerts - beatles.ru
Earnings Recap: What is Halozyme Therapeutics Inc.’s book value per share - خودرو بانک
Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today - sharewise.com
Can a trend reversal in Halozyme Therapeutics Inc. lead to recoveryQuarterly Earnings Report & Expert Curated Trade Ideas - Newser
Volatility clustering patterns for Halozyme Therapeutics Inc.July 2025 Weekly Recap & Fast Gain Stock Trading Tips - Newser
What’s next for Halozyme Therapeutics Inc. stock priceJuly 2025 Momentum & Community Supported Trade Ideas - Newser
Published on: 2025-09-01 15:56:05 - Newser
Is Halozyme Therapeutics Inc. stock ready for a breakoutQuarterly Portfolio Review & Entry Point Confirmation Signals - Newser
Live Chart Scan Detects Wedge Pattern in Halozyme Therapeutics Inc. getLinesFromResByArray error: size == 0 - 더경남뉴스
A | Can Halozyme Therapeutics, Inc. outperform under higher oil prices - خودرو بانک
What candlestick patterns are forming on Halozyme Therapeutics Inc.July 2025 Review & Consistent Income Trade Ideas - Newser
Published on: 2025-08-31 22:36:40 - beatles.ru
Halozyme Therapeutics Inc Azioni (HALO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Halozyme Therapeutics Inc Azioni (HALO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Torley Helen | PRESIDENT AND CEO |
Sep 03 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
| Torley Helen | PRESIDENT AND CEO |
Sep 04 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
| Torley Helen | PRESIDENT AND CEO |
Sep 03 '25 |
Sale |
74.44 |
20,000 |
1,488,726 |
733,719 |
| Torley Helen | PRESIDENT AND CEO |
Sep 04 '25 |
Sale |
74.04 |
20,000 |
1,480,772 |
733,719 |
| Torley Helen | PRESIDENT AND CEO |
Sep 02 '25 |
Sale |
73.76 |
20,000 |
1,475,128 |
733,719 |
| Connaughton Bernadette | Director |
Sep 02 '25 |
Sale |
73.68 |
4,000 |
294,736 |
46,952 |
1.40%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):